Southwest Oncology Group study of mitoxantrone for treatment of patients with advanced adenoid cystic carcinoma of the head and neck.
Eighteen patients are evaluable for response in a Phase II trial of Mitoxantrone for advanced adenoid cystic carcinoma of the head and neck. One patient had a complete response; there were no partial responses. Twelve patients had stable disease for 3 or more months. There was no significant anti-tumor activity of Mitoxantrone in the group of patients with adenoid cystic carcinoma, all of whom were previously heavily treated with surgery, chemotherapy and/or radiation therapy.
Mattox
D E
DE
Johns Hopkins Hospital, Baltimore, MD.
Von Hoff
D D
DD
Balcerzak
S P
SP
D000328:Adult; D000368:Aged; D003528:Carcinoma, Adenoid Cystic / Q000188:drug therapy* / Q000401:mortality; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000009:adverse effects / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D015996:Survival Rate
D008942:Mitoxantrone